Article

Atopic Dermatitis More Prevalent in Female Patients at 24 Years

Author(s):

Swedish investigators noted differences in the prevalence of atopic dermatitis among the 2 sexes, and considered it important data for clinicians that treat patients with the disease.

Natalia Ballardini, MD

Natalia Ballardini, MD

A new Swedish study observed the prevalence of atopic dermatitis in young adults across the country and found the disease was more prevalent in female patients than males at 24 years old.

However, adult onset of atopic dermatitis appeared to be equally prevalent among the 2 sexes in young adulthood.

A recent systematic review reported the 12-month prevalence of the disease to range from 1.3% and 22.7%, based on symptoms. However limited knowledge regarding atopic dermatitis in young adults exists in Sweden, in addition to knowledge gaps in the course of the disease beyond childhood.

Investigators led by Natalia Ballardini, MD, Institute of Environmental Medicine at the Karolinska Institute, detailed the prevalence and characteristics of atopic dermatitis among young adults in a Swedish population-birth cohort.

The Methods

The BAMSE project was a population-based cohort from Stockholm that recruited newborn children from 1994 to 1996 and followed up to 24 years old. The cohort was comprised of 4089 infants, totaling 75% of all eligible subjects.

Questionnaires were completed by the parents of eligible boy (2065) and girl (2024) patients, which included questions on background factors. Follow-up questions regarding atopic dermatitis, asthma, and rhinitis were issued to parents and participants a 1, 2, 4, 8, 12, and 16 years of age.

By the age of 24 years old, participants were tasked with answering another questionnaire regarding dry skin, itchy skin rash, affected localization, and nocturnal sleep-disturbance due to itch. Questions regarding treatments for the disease were also issued.

After the 24-year follow-up of the BAMSE cohort was finalized in 2019, a total of 3069 participants were included in the study.

Among these participants, those with visible atopic dermatitis were asked to complete Patient-Oriented Eczema Measure (POEM) to assess the severity of their condition.

A total of 2264 (74%) participated in the clinical examination and data on IgE sensitization was available for 2229 (73%) participants.

The Findings

In the study-population, 543 of 3,055 individuals (17.8 %, 95% CI: 16.4% -19.1%) fulfilled the criteria to be classified as having had atopic dermatitis in the past year.

Investigators observed that atopic dermatitis was significantly more prevalent among females compared with males (20.5 % versus 14.8 %, p<0.0001).

Additionally, among those who participated at the clinical examination, 8.0 % (95 % CI: 6.8 % - 9.2 %) had ongoing atopic dermatitis (females 8.5 %, males 7.3 %, p=0.33).

A majority of participants had lived with their disease in early childhood, with symptoms debuting at the age of 2 years. A history of onset atopic dermatitis was more common in males than females (69.5 % versus 60.0 %, p<0.02), and more males than females with the disease had a history of persistent atopic dermatitis (30.5 % versus 21.2 %, p<0.01).

Investigators noted that IgE-sensitization was less common among females than males (61.3% versus 79.6%, p<0.0001), and male sex was associated with increased odds for the disease for the first year of life (OR 1.31, 95% CI; 1.10–1.56), and decreased odds in adolescence and young adulthood (OR 0.66,95% CI; 0.55–0.80).

“Our findings demonstrate that in some aspects atopic dermatitis differ between males and females and this is important to consider for clinicians that treat patients with AD, and for future studies of AD,” the team wrote.

Related Videos
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
© 2024 MJH Life Sciences

All rights reserved.